Cluj-Napoca, Romania
Cluj-Napoca, Romania

Time filter

Source Type

News Article | November 14, 2016

BROSSARD, QUEBEC--(Marketwired - Nov. 14, 2016) - Diagnos Inc. ("DIAGNOS" or "the Corporation") (TSX VENTURE:ADK), a leader in healthcare technical services including screening, software and algorithm development, data analysis, and image processing, celebrates today the World Diabetes Day by announcing a pilot in partnership with Mexico's National Social Security System. The public-private partnership (PPP) for the pilot involves both sides commitments: from one side the Mexican Social Security Institute's (IMSS for Spanish) Head Office, Entailment Department, Department of Chief Medical Officer along with its several divisions: Special National Health Projects, Primary-Secondary-and Tertiary level of attention divisions, as well as the National Coordination of Ophthalmology; from the other side DIAGNOS' proprietary artificial intelligence Computer Assisted Retinal Analysis (CARA) and its Wellness Program: hardware, CARA platform and specialized staff in eye care to manage diabetics and operate our technology, IT Department, senior management entrusted by its shareholders and board of directors. IMSS provides social security to over 71 Million people nationwide in Mexico. The purpose of the pilot for the public health authority is to collect evidence such as avoidance of blindness of at least 95% of diabetics' cases, avoid wrong referral of patients to the specialist, time reduction for an appointment to the specialist within the following 48 hours (instead of 8 months), control and monitor of diabetics, provide a solid database, unburden diabetes costs which nowadays surpass $ 96 Million Mexican pesos per day (approx. $ 4.6 Million US dollars), among others. As well specialists and observers of the pilot will certify CARA's performance for automatic detection, biometrics and telemedicine friendly connectivity, by accessing randomly to patients' results. In the automatic detection the specialists will provide feedback in terms of sensitivity and specificity minding that DIAGNOS has quality certifications and approvals from COFEPRIS in Mexico, FDA in the US, Health Canada, to mention a few. In biometrics and telemedicine friendly connectivity, the specialists will look after its integration to IMSS Digital program on how doctors and patients interact by safeguarding the management of information. "DIAGNOS is proud to collaborate with IMSS for a pilot starting at World Diabetes Day: in 3 weeks we'll screen patients within 2 family medicine units (UMF) of IMSS' first level of attention. Both parties are investing time and resources to run successfully run it in order to set the principles for a strategic alliance by fitting DIAGNOS' Wellness Program powered by our CARA platform into IMSS' flagship diabetes programs: DiabetIMSS and PrevenIMSS. We're confident that the outcome of this pilot will be beneficial for the Mexican diabetics entitled with social security coverage within the national territory," said André Larente, President of DIAGNOS. Mr. Larente also added "Our health IT technology was made to be accessible to all people around the world with diabetes or pre-diabetes condition, our vision is to provide universal coverage and we keep our efforts every day to achieve it". After gathering conclusions from the pilot, IMSS will evaluate the feasibility for a multi-annual contract starting in 2017 with different business models: fix in clinics, mobile and the ignition of the National Ophthalmology Centre in order to provide specific eye care to a minimum of 1.5 to 5 Million diabetics. Founded in 1998, DIAGNOS is a publicly traded Canadian corporation with a mission to commercialize technologies combining contextual imaging and traditional data mining thereby improving decision making processes. DIAGNOS offers products, services, and solutions to clients in a variety of fields including healthcare and natural resources. CARA is a tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care (POC) and comprises: image upload, image enhancement automated pre-screening, grading by a specialist, and referral to a specialist. CARA's image enhancement algorithms make standard retinal images sharper, clearer, and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients, in real-time and has been approved by regulatory authorities including Health Canada, US Food and Drug Administration, and the European Union. This document contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements. Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. For further information, please contact DIAGNOS, visit our website at, or visit the SEDAR website at

News Article | December 2, 2016

This report studies ENT Chairs in Global Market, especially in United States, Canada, Mexico, Germany, France, UK, Italy, Russia, China, Japan, India, Korea, Southeast Asia, Australia, Brazil, Middle East and Africa,  focuses on the top Manufacturers in each country, covering  Atmos Medical  Heinemann Medizintechnik  Haag Streit  Optomic  Chammed  Global Surgical  BOKEER  Mega Medical  Nagashima Medical  Arsimed Medical  Innotech Medical  Olsen  Tecnodent  UMF Medical Market Segment by Countries, this report splits Global into several key Countries, with sales, revenue, market share of top players in these Countries, from 2012 to 2017 (forecast), like  1 United States  2 Canada  3 Mexico  4 Germany  5 France  6 UK  7 Italy  8 Russia  9 China  10 Japan  11 India  12 Korea  13 Southeast Asia  14 Australia  15 Brazil  16 Middle East  17 Africa Split by Product Types, with sales, revenue, price, market share of each type, can be divided into  Manual ENT Chairs  Powered ENT Chairs Split by applications, this report focuses on sales, market share and growth rate of ENT Chairs in each application, can be divided into  Hospitals  Clinics 2017-2022 Global Top Countries ENT Chairs Market Report  1 ENT Chairs Market Overview  1.1 Product Overview and Scope of ENT Chairs  1.2 ENT Chairs Segment by Types  1.2.1 Global Sales Market Share of ENT Chairs by Types in 2015  1.2.2 Manual ENT Chairs  1.2.3 Powered ENT Chairs  1.3 ENT Chairs Segment by Applications  1.3.1 ENT Chairs Consumption Market Share by Applications in 2015  1.3.2 Hospitals  1.3.3 Clinics  1.4 ENT Chairs Market by Countries  1.4.1 United States Status and Prospect (2012-2022)  1.4.2 Canada Status and Prospect (2012-2022)  1.4.3 Germany Status and Prospect (2012-2022)  1.4.4 France Status and Prospect (2012-2022)  1.4.5 UK Status and Prospect (2012-2022)  1.4.6 Italy Status and Prospect (2012-2022)  1.4.7 Russia Status and Prospect (2012-2022)  1.4.8 China Status and Prospect (2012-2022)  1.4.9 Japan Status and Prospect (2012-2022)  1.4.10 India Status and Prospect (2012-2022)  1.4.11 Korea Status and Prospect (2012-2022)  1.4.12 Southeast Asia Status and Prospect (2012-2022)  1.4.13 Australia Status and Prospect (2012-2022)  1.4.14 Brazil Status and Prospect (2012-2022)  1.4.15 Mexico Status and Prospect (2012-2022)  1.4.16 Middle East Status and Prospect (2012-2022)  1.4.17 Africa Status and Prospect (2012-2022)  1.5 Global ENT Chairs Overview and Market Size (Value) (2012-2022)  1.5.1 Global Market ENT Chairs Overview  1.5.2 Global Market ENT Chairs Revenue (Million USD) and Growth Rate (2012-2022)  2 Global ENT Chairs Sales, Revenue (Value) and Market Share by Manufacturers  2.1 Global ENT Chairs Sales and Market Share in 2015 and 2016 by Manufacturers  2.2 Global ENT Chairs Revenue and Market Share by Manufacturers in 2015 and 2016  2.3 Global ENT Chairs Average Price by Manufacturers in 2015 and 2016  2.4 Global ENT Chairs Manufacturing Base Distribution, Sales Area, Product Types by Manufacturers  2.5 ENT Chairs Market Competitive Situation and Trends  2.5.1 ENT Chairs Market Concentration Rate  2.5.2 ENT Chairs Market Share of Top 3 and Top 5 Manufacturers  2.5.3 Mergers & Acquisitions, Expansion  3 Global ENT Chairs Sales, Revenue (Value) by Countries, Type and Application (2012-2017)  3.1 Global ENT Chairs Sales, Revenue and Market Share by Countries (2012-2017)  3.1.1 Global ENT Chairs Sales and Market Share by Countries (2012-2017)  3.1.2 Global ENT Chairs Revenue and Market Share by Countries (2012-2017)  3.1.3 Global ENT Chairs Price by Countries (2012-2017)  3.2 Global ENT Chairs Sales, Revenue, Market Share and Price by Type (2012-2017)  3.2.1 Global ENT Chairs Sales and Market Share by Type (2012-2017)  3.2.2 Global ENT Chairs Revenue and Market Share by Type (2012-2017)  3.2.3 Global ENT Chairs Price by Type (2012-2017)  3.3 Global ENT Chairs Sales and Market Share by Application (2012-2017)  3.4 Global Market ENT Chairs Sales, Revenue, Price and Gross Margin (2012-2017) For more information or any query mail at [email protected]

Tarnita D.,University of Craiova | Popa D.,University of Craiova | Dumitru N.,University of Craiova | Tarnita D.N.,U.M.F. | And 2 more authors.
Mechanisms and Machine Science | Year: 2010

In this paper we are presenting the results of the research based on dynamic simulation of human knee virtual model. Starting from the parts realized with computer tomography help, there were realized virtual models for the femur, tibia, meniscus and ligaments that form the complex human knee joint, and their meshing in finite elements. There are presented comparative stress diagrams for the normal walking and for the case of sectioned anterior crisscross ligament. Maps of stress are presented for the whole joint and for its components, to different movement moments. 3DP rapid prototyping technology is used to obtain the components of the human knee joint necessary for future experimental research. © Springer Science+Business Media B.V. 2010.

Ciocoiu M.S.,UMF | Cojocaru M.,Ovidius University | Ciocoiu S.V.,Occupational health specialty Science Oil Terminal S.A
Romanian Biotechnological Letters | Year: 2010

A survey has been performed focusing on stress related manifestations regarding magistrates for the purpose of knowing the reactions and their consequences over the state of health. In the survey a sample of 176 magistrates has been taken, representative for Constanţa County, out of whom 92 judges and 84 prosecutors, 70 men and 106 women, with ages ranging between 20-60 years and a length of service in magistracy between 1-25 years. As a supplement to a previous survey by which stress factors regarding magistrates have been evaluated, a questionnaire validated by a pre-test has been used, comprising 126 manifestations that may be related to stress, classified into 6 categories regarding: personality, conduct, cognitive area, physiological and physio-pathological reactions, the state of health and work capacity. The most frequent have proven to be the manifestations in the field of personality, conduct and state of health. The categories, types o manifestations and their relation to various factors, useful for the orientation of occupational health actions and of labor medicine services have been analyzed. © 2010 University of Bucharest.

Tiotiu A.,Nancy University Hospital Center | Mairesse O.,Vrije Universiteit Brussel | Hoffmann G.,Sleep Unit | Todea D.,UMF | Noseda A.,CHU Brugmann
Pneumologia | Year: 2011

Background: Until now, studies about body position and nocturnal breathing abnormalities have been restricted to comparing supine versus lateral positions. Objectives: In this retrospective study, we systematically evaluated the effect of body position on nocturnal breathing in 105 patients with a sleep apnea hypopnea syndrome (SAHS). Methods: All the patients had an apnea hypopnea index > 10/h, as judged from polysomnography performed in the sleep laboratory. A thoracic sensor allowed to detect nine distinct body positions: supine (S), supine right (SR), right (R), prone right (PR), prone (P), prone left (PL), left (L), supine left (SL) and sitting upward (UP). Respiratory variables (number of obstructive, central and mixed apneas, of hypopneas and of desaturations, all expressed as an index per hour of total sleep time) were evaluated versus the body positions, using the non-parametric Kruskal-Wallis H method. Pairwise comparisons were performed using Mann-Whitney U tests. Results: Most of the total sleep time (45%) was spent supine. A significant effect of body position was found for all the respiratory variables. Breathing was better in the intermediate SR and SL positions than S, and also better in PR and PL positions than, respectively, R and L. All the respiratory variables gradually improved when gradualling moving from the S to the P position. Conclusions: A nine position sensor, able to define intermediate positions in addition to the basic cardinal positions, is useful in the sleep laboratory. Using such a sensor, we found in SAHS patients that nocturnal breathing improves as a continuum from the S to the P position.

Nastase-Melicovici D.,Spitalul Clinic Judetean de Urgenta Mures | Macarie C.,UMF | Coman S.,Spitalul Clinic Judetean de Urgenta Mures | Mariana T.,UMF
Annals of the Romanian Society for Cell Biology | Year: 2012

The purpose of our study was to determine left ventricular mass index with transthoracic echocardiography in patients with congestive heart failure, in stages (ussual upper) when renal dysfunction was or not asociated. Materials and Methods: we consider renal dysfunction when rate of glomerular filtration <60 ml/min.Glomerular filtation rate was measured in 47 patients with ischemic heart failure and an ejection fraction <40%. For each patient we registered clinical examination, laboratory tests (serum hemoglobin, creatinin, potassium and albumin), echocardiogram and echocardiography (left ventricular ejection fraction (EF), LV mass, and LV mass index), body mass index (BMI) and total body water (TBW). Results: number of patients with RD was 21 representing a prevalence of 44,68%. There was a greater prevalence for elder subjects. These patients has lower level of hemoglobin and serum albumin but potasium, serum creatinine levels, body mass index (BMI) and total body water (TBW) were higher. Left ventricular mass determined by echocardiography was greater in patients with RD (p= 0.06). Comparison of their drug therapy revealed significant statisticaly diferences only for use of beta blockers and amiodarone. Conclusions: Renal dysfunction is a frequent and seems inevitable asociation in patients with congestive heart failure with ejection fraction of left ventricle under 40 percentage, and is associated with distinctive features that may explain some major undesirable clinical aspects. Patients with CHF and renal dysfunction has left ventricular mass increased.

Coman H.,II Surgical Clinic Cluj Napoca | Andercou A.,II Surgical Clinic Cluj Napoca | Popa C.,UMF | Nagy A.,USAMV
Annals of the Romanian Society for Cell Biology | Year: 2012

The restoration of the bile circulation in obstructive jaundice is a problem for today's surgery, even though there are many ways of doing it. Besides the bilio-digestive anastomosis (BDA), that are so frequently used, a less experimented and used technique is the using of a vascular graft as a mean to establish the communication between the bile ducts and the small intestine. To obtain an OJ and to perform a biliary-digestive bypass (BDB) as an alternative to the classical BDA, using a 4 mm Gore-Tex vascular graft. We studied 15 rabbits, randomly divided in 3 groups: A, B, C. We imagined 5 phases(F1-F5): F1-the determination of white, red and platelets blood cells, serum bilirubin, alkaline phosphatase, gamma GT, ASAT, ALAT, serum amylase, urea, creatinine and glucose.; ligation of distal bile duct. F2-7 days from F1-blood samples for the same determinations; performing the by-pass using 4mm Gore-Tex vascular graft; liver biopsy. F3, F4, F5 at 14, 21 and 28 days from F1-blood samples for the same determinations; liver biopsy at 21 days. We obtained distal bile duct dilatation and increasing of the blood parameters investigated; at 7 days after the bile-duct ligation we performed the bypass between the hepatic duct and jejunum and between distal bile duct and duodenum; at 21-28 days the blood parameters were between normal values. The liver's microscopic pathological aspect was of bile stasis and showed a minimal improvement after 21 days. The performing of the bypass reestablishes the bile flow and thus the improvement of the blood parameters.

AbstractIntroduction Iron administered in anemia and chronic kidney disease (CKD) an estimated 500-600 mg/month, the determination of iron kinetics (CH), transferrin saturation index (IST) and ferritin are necessary. Objetive Evaluate adherence to guidelines for use of iron in anemia and CKD in hemodialysis (HD). Methods A total of 117 patients with CKD, HD and iron supplementation: Group A, 2 HD session, Group B 3 sessions HD. CH, IST, ferritin, Hb, reticulocyte and PFH were determined. Results Men: 58%, age 37 + 16 SD, Hb 118 c/dl and reticulocyte 0,9%. Doses of 200 mg/week/3 iron years. Group A: IST 100%; Group B: 90%. Both greater IST, transferrin group to 122 mg/dl; group B 137 mg/dl. Normal PFH. Conclusion Iron not be calculated, monitored or supervised in the medium term. And not attached to recommended guidelines. © 2013 SEDYT.

Mihalache L.,UMF | Graur L.I.,UMF | Popescu D.S.,2. Deleni Individual Medical Practice | Boiculese L.,UMF | And 2 more authors.
Acta Endocrinologica | Year: 2012

Background. The literature contains several definitions of the metabolic syndrome, different from one another through the components included and the reference ranges considered normal. The aim of this study is to evaluate the prevalence of the metabolic syndrome and its components in a rural community from the North-East region of Romania. Methods. The study included 3248 persons from the rural environment. The data recorded regarded gender, age, anthropometric parameters (weight, waist circumference, body mass index), arterial blood pressure, and laboratory findings. The defining criteria for the metabolic syndrome used were IDF 2005 in comparison with the criteria NCEP-ATP III. Results. Over half of the studied population presents excess body weight, the prevalence of obesity (Body Mass Index - BMI≥30kg/m2) being 17.5% with a proportional relationship between age and BMI value (p<0.001), as well as between age and waist circumference value (p<0.001). The prevalence of the metabolic syndrome according to IDF criteria is 16.3% and 14.2% according to NCEP-ATP III criteria. Irrespective of the BMI value, there is an individual increase in the number of cardiovascular risk factors parallel to the increase of the WC. Conclusions. The metabolic syndrome is frequently encountered in the clinical practice and the use of the IDF definition criteria allows a wider identification of the patients with high cardiometabolic risk. This is the group of people that need to be targeted by the diagnostic and treatment of important cardiometabolic pathology.

After several decades without any notable progress, there are encouraging results in research and development of anti-TB drugs, the result of a large number of projects now in competition. Along with developing new drugs to treat tuberculosis (TMC207, SQ109, LL3858) are being reassessed others to optimize their effectiveness in order to shorten and simplify therapy (rifampin and rifapentine) and three other drugs, currently used for other indications, were forwarded towards TB (gatifloxacin and moxifloxacin, linezolid). Time to approval as a antiTB drug is 10-15 years, consisting of phases of preclinical and clinical research. Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis resulted in a small but statistically nonsignificant increase in 8 th-week culture negativity. TMC207, a diarylquinoline with a unique way to address Mycobacterial ATP synthetase, shows high activity in vitro against Mycobacterial strains sensitive or resistant to all drugs in the first and second line, including fluoroquinolones, demonstrating exceptional qualities in vivo against several species of mycobacteria, in various animal models. TMC207 was added to a basic standard regimen in a study of MDR-TB patients. After two months and satisfactory tolerability, sputum conversion rate in culture was 48% (vs 9% in the placebo group). Two nitroimidazole (PA-824 and OPC-67683) are currently in clinical development. PA-824 demonstrated good safety and tolerability in adult patients with pulmonary TB in South Africa, when given once daily for 7 days. Associating isoniazid, would prevent the selection of mutants resistant to Isoniazid. Linezolid 600 mg is currently being tested in a Phase II for treatment of XDR-TB in the Republic of Korea. PNU-100480, analogous to the previous one, has the potential to significantly shorten the treatment in cases where there is sensitivity and in those with resistance to drugs. 300 mg dose is under investigation in a phase II pilot study in MDR-TB in South Africa. With this interest and commitment, it appears that there is a chance of having a new drug available soon.

Loading UMF collaborators
Loading UMF collaborators